Thrombosis Articles & Analysis
38 news found
Ultimately, these diverse models are developed to bridge the gap between laboratory research and clinical application for most cardiovascular diseases such as atherosclerosis, hypertension, thrombosis, heart failure, and cardiovascular infection. Utilizing a range of specialized animal-specific hematology analyzers, biochemical analyzers, small animal PET/MRI imaging systems, ...
Pulmonary embolism (PE) can be a life-threatening condition that affects around 900,000 people in the United States every year.2 In most cases, PE is caused by blood clots in the legs, called deep vein thrombosis, that travel to the lungs.2 Patients with submassive or intermediate-risk PE account for 35% to 55% of hospitalized patients with PE and have a mortality rate of 3 to ...
It is currently being evaluated as a potential once-daily oral Factor XIa (FXIa) inhibitor in thrombosis prevention with the goal to reduce clot formation while leaving the body’s ability to respond to bleeding intact. ...
ByBayer AG
Xarelto is approved for more venous and arterial thromboembolic (VAT) conditions than any other NOAC: The prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (AF) with one or more risk factors The treatment of pulmonary embolism (PE) in adults The treatment of deep vein thrombosis (DVT) in adults The prevention of recurrent PE ...
ByBayer AG
All patients required therapy because of dangerous narrowing of the carotid artery and received the nowadays standard basic therapy with the blood platelet inhibitors acetylsalicylic acid (Aspirin©) and/or clopidogrel to prevent renewed vascular occlusion (thrombosis). The vasoconstrictions were removed surgically or by inserting stents, or they were treated with the best ...
Strong market uptake of Nubeqa and Kerendia Asundexian projected peak sales of more than five billion euros as treatment option for thrombosis and stroke prevention High-value late-stage development portfolio Positive study outcomes from cell & gene therapy pipeline would provide potential upside Shift of resources enhances commercialization and competitiveness Acquired ...
ByBayer AG
It’s been used for the first time – on Jackie Field, from Eltham south east London, and cured her of deep vein thrombosis. ITV’s Rags Martel explains how it works. WORLD'S FIRST DVT CLOT REMOVING PROCEDURE IN LONDON ...
Rivaroxaban Rivaroxaban, as an antithrombotic drug, is widely used in the treatment and prevention of deep vein thrombosis (DVT) symptoms prior to hip or knee replacement surgery, treatment of venous thromboembolism (VTE) and nonvalvular atrial fibrillation, as well as treatment of DVT and pulmonary embolism (PE). ...
The design is expected to enable safe percutaneous implantation, with low risk of bleeding, stroke, and pump thrombosis, while providing sustained symptom relief, reduced re-hospitalizations and improved overall quality of ...
DEFIANCE is a randomized controlled trial (“RCT”) comparing the clinical outcomes of patients with iliofemoral deep vein thrombosis (“DVT”) treated with the ClotTriever System versus anticoagulation only. ...
FXIa inhibitors that selectively modulate coagulation through FXIa inhibition could represent a fundamentally new approach to antithrombotic treatment, as they prevent thrombosis yet still allow haemostatic clots that are crucial to repair injury. ...
ByBayer AG
The design is expected to enable safe percutaneous implantation, with low risk of bleeding, stroke, and pump thrombosis, while providing sustained symptom relief, reduced re-hospitalizations and improved overall quality of life. ...
The design is expected to enable safe percutaneous implantation, with low risk of bleeding, stroke, and pump thrombosis, while providing sustained symptom relief, reduced re-hospitalizations and improved overall quality of life. ...
Xarelto is approved for more venous and arterial thromboembolic (VAT) conditions than any other NOAC: The prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (AF) with one or more risk factors The treatment of pulmonary embolism (PE) in adults The treatment of deep vein thrombosis (DVT) in adults The prevention of recurrent PE ...
ByBayer AG
The device is designed to avoid well-documented risks of perforation, migration, fracture, and thrombosis currently associated with IVC filters. Such safety issues have been the focus of the FDA-mandated PRESERVE (Predicting the Safety and Effectiveness of Inferior Vena Cava Filters) Study of IVC filters from six manufacturers. ...
The components of target lesion revascularization (TLF) were low in both women and men and numerically favored females, including target vessel-myocardial infarction (8.5 percent vs 9.7 percent), target lesion revascularization (2.9 percent vs 4.2 percent) and stent thrombosis (0 percent vs 1.2 percent). “Given the established safety profile of IVL and the high rates of ...
The study design will be presented at the International Society of Thrombosis and Hemostasis (ISTH) Congress in London, U.K in July 2022 and is available at https://www.clinicaltrials.gov/ct2/show/NCT04676048. ...
NETs have been shown to be associated with several pathological processes including, fibrosis, ischemic stroke, preeclampsia, thrombosis, cancers and other autoimmune diseases. Jubliant Therapeutics Inc. is targeting PAD4 inhibition as a novel strategy to treat inflammatory diseases, cancer progression and metastasis. ...
Her expertise focuses on therapeutic areas of cardiovascular disease (thrombosis, hemostasis, atherosclerosis, coagulation, hyperlipidemia), inflammation, autoimmune diseases, and hematologic malignancies. She is internationally recognized for her scientific accomplishments (publications, patents, and invited lectures) in the field of thrombosis and ...
LMWHs are injectable anticoagulant drugs used primarily to treat and prevent deep vein thrombosis and pulmonary embolism. Redesca has more than 8 years of proven in-market safety internationally. and more than 150 million patient days treated in Europe alone. ...